Vivo aims to aid US/Chinese cross-border pacts with $375M fund
This article was originally published in Scrip
Executive Summary
With the closing of a new $375 million fund, Vivo Ventures is not only eyeing to invest in clinical and commercial stage drug and device makers in the US and China, it also is aiming to facilitate cross-border partnerships between companies in those countries, said managing partner Dr Albert Cha.